Heart Health

This news channel includes content on cardiovascular disease prevention, cardiac risk stratification, diagnosis, screening programs, and management of major risk factors that include diabetes, hypertension, diet, life style, cholesterol, obesity, ethnicity and socio-economic disparities.
 

cocaine heart failure HFrEF LVEF hospitalizations beta-blockers hypertension cardiology

How cocaine use affects outcomes for hospitalized heart failure patients

When cocaine users are hospitalized for heart failure, what should physicians expect? Are beta-blockers an effective treatment strategy? 

Abbott’s FreeStyle Libre 3 glucose monitor gains FDA clearance

Regulatory Roundup: FDA clears 2 new devices, grants breakthrough designation to advanced AI model

Catch up on several recent FDA announcements, including an update on the agency's response to the COVID-19 pandemic. 

Examples of mitral annual calcification (MAC) visualized using echocardiography. Image from the journal Echocardiography.

Mitral annulus calcification more than doubles a patient’s risk of heart valve disease

"For clinicians, suspicion for valve diseases should be increased and evaluations carefully performed for patients with MAC," according to one Mayo Clinic cardiologist.

metformin chemodynamic therapy type 2 diabetes Nano Research

A new use for metformin? Popular type 2 diabetes medication may also improve cancer and infection therapies

Metformin appears to improve the impact of chemodynamic therapy, according to a new analysis in Nano Research. 

Empagliflozin may reverse vascular aging, lower CVD risk

The SGLT2 inhibitor is already known as an effective medication for both type 2 diabetes and heart failure.

The FDFA has cleared tirzepatide (Mounjaro) from Eli Lilly for the treatment of diabetes.

FDA approves tirzepatide, Eli Lilly’s new type 2 diabetes drug, and the company shares an estimated price

The medication, sold under the name Mounjaro, will be available in six different doses and come in an auto-injector pen.

Intermittent fasting helps breast cancer survivors limit their CVD risk

A new study published in the Journal of the American College of Cardiology examined how a breast cancer survivor's eating schedule may impact their risk of cardiac events. 

Renal denervation is associated with improved blood pressure (BP) control and a reduced risk of adverse cardiovascular outcomes, according to two late-breaking clinical trials presented at EuroPCR 2022 in Paris. Both clinical trials focused on three-year data related to Medtronic’s Symplicity Spyral Renal Denervation (RDN) System, which was designed to lower BP through the use of a curling catheter that ablates overactive nerves.

Renal denervation improves blood pressure control, lowers risk of adverse cardiovascular outcomes

Two late-breaking clinical trials at EuroPCR 2022 in Paris focused on the potential benefits of renal denervation.